Table 1 CAV3 mutations identified in patients affected by LGMD-1C

From: Caveolinopathies: from the biology of caveolin-3 to human diseases

Nt. change

Aa. change

Phenotype

Ref.

N-terminal domain

 c.77G>A

p.R26Q

LGMD

Figarella Branger et al57

 c.77G>A

p.R26Q

LGMD, RMD

Fee et al60

 c.81C>A

p.D27E

LGMD, RMD, DM

Fischer et al61

 c.96C>G

p.N32K

LGMD

Sugie et al58

 c.114+2T>C*

p.K37X

LGMD

Muller et al44

 c.128T>A

p.V43E

LGMD

Sugie et al58

 c.133G>A

p.A45T

LGMD

Herrmann et al12

 c.163G>A*

p.G55S

LGMD

McNally et al42

Scaffolding domain

 c.183C>A

p.S60R

LGMD,H-CK

Fulizio et al48

 c.187A>C

p.T63P

LGMD

Matsuda et al56

 c.187_194del

p.TFT63-65del

LGMD

Minetti et al54

 c.216C>G

p.C71W

LGMD

McNally et al42

Membrane-spanning domain

 c.233C>T*

p.T77M

LGMD

Traverso et al47

 c.277G>A*

p.A92T

LGMD- RMD

Kubisch et al43

 c.290_293del

p.F96del

LGMD, RMD, H-CK

Cagliani et al78

 c.314C>T

p.P104 L

LGMD

Minetti et al54

  1. Abbreviations: H-CK, hyperCKemias, (s) sporadic, (f) familiar; RMD, rippling muscle disease; LGMD, limb-girdle muscular dystrophy; DM, distal myopathy; *, homozygous mutation.